Diminazene

Diminazene

SCHEMBL871301

N=C(N)c1ccc(N=NNc2ccc(C(=N)N)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMPRSS2 O15393 1/20 1.00
FURIN P09958 1/20 1.00
AOC1 P19801 1/20 1.00
SAT1 P21673 1/20 1.00
ACE2 Q9BYF1 1/20 1.00
CYP1B1 Q16678 4/20 0.59
CYP1A1 P04798 3/20 0.59
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
HPGD P15428 2/20 0.50
PRSS1 P07477 8/20 0.47
F2 P00734 3/20 0.47
PRSS2 P07478 3/20 0.47
PRSS3 P35030 3/20 0.47
TMPRSS6 Q8IU80 3/20 0.47
ST14 Q9Y5Y6 3/20 0.47
NOS3 P29474 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diminazene SCHEMBL120719 1.00 TMPRSS2 (1.00) TMPRSS2FURINAOC1SAT1ACE2
Diminazene SCHEMBL22491202 0.98 TMPRSS2 (0.96) TMPRSS2FURINAOC1SAT1ACE2
Diminazene SCHEMBL22491199 0.98 TMPRSS2 (0.96) TMPRSS2FURINAOC1SAT1ACE2
SCHEMBL18999169 0.92 TMPRSS2 (0.84) TMPRSS2FURINAOC1SAT1ACE2
SCHEMBL12348395 0.92 TMPRSS2 (0.84) TMPRSS2FURINAOC1SAT1ACE2
SCHEMBL19006339 0.92 TMPRSS2 (0.84) TMPRSS2FURINAOC1SAT1ACE2
SCHEMBL19006330 0.91 TMPRSS2 (0.84) TMPRSS2FURINAOC1SAT1ACE2
SCHEMBL18999171 0.91 TMPRSS2 (0.84) TMPRSS2FURINAOC1SAT1ACE2
Diminazene SCHEMBL13836545 0.91 TMPRSS2 (0.82) TMPRSS2FURINAOC1SAT1ACE2
SCHEMBL22670488 0.89 TMPRSS2 (0.79) TMPRSS2FURINAOC1SAT1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10203334-B2 Methods and compositions related to nucleic acid binding assays Nubad, LLC (US) 2019-02-12 US claimed
US-20160282357-A1 METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS Nubad, LLC 2016-09-29 US claimed
US-9017943-B2 Methods and compositions related to nucleic acid binding assays NUBAD LLC (US) 2015-04-28 US claimed
US-20140330001-A1 METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS Nubad, LLC (US) 2014-11-06 US claimed
US-20140024137-A1 METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS NUBAD LLC 2014-01-23 US claimed
WO-2013083813-A2 MODULATORS OF SPERMINE/SPERMIDINE N'-ACETYLTRANSFERASE (SSAT) AND SSAT ASSOCIATED PROTEINS FOR USE IN PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS Universität Zürich (CH) 2013-06-13 WO claimed
US-20100323993-A1 USES OF PENTAMIDINE AND RELATED COMPOUNDS STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON 2010-12-23 US claimed
WO-2025245089-A1 PROCESSES FOR PREPARING TETRALIN COMPOUNDS ARCUS BIOSCIENCES, INC. (US) 2025-11-27 WO disclosed
US-20250288613-A1 COMPOSITIONS AND METHODS TARGETING SAT1 FOR ENHANCING ANTI-TUMOR IMMUNITY DURING TUMOR PROGRESSION THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) 2025-09-18 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
CN-118632835-A Tryptamine compositions and methods 赛本爱尔兰有限公司 2024-09-10 CN disclosed
US-20090048427-A1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS EPOCH BIOSCIENCES, INC. (US) 2009-02-19 US disclosed
US-7297495-B2 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES, INC. (US) 2007-11-20 US disclosed
US-7297495-B2 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES, INC. (US) 2007-11-20 US disclosed
US-20070166723-A1 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES INC. (US) 2007-07-19 US disclosed
US-20070166723-A1 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES INC. (US) 2007-07-19 US disclosed
US-20050014708-A1 Inhibition of viral replication by targeting RNA-DNA complexes UNIVERSITY OF MEDICINE AND DENISTRY OF NEW JERSEY 2005-01-20 US disclosed
US-20030069194-A1 Inhibition of viral replication by targeting RNA-DNA complexes UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070166723-A1 Hybridization-triggered fluorescent detection of nucleic acids DDX21, RNGTT, NOP2 TMPRSS2 3449/4885FURIN 2261/4885AOC1 2297/4885
US-20090048427-A1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS DDB1, LIG3, MSH2 TMPRSS2 2264/4885FURIN 3595/4885AOC1 3751/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 TMPRSS2 219/4885FURIN 158/4885AOC1 2396/4885
US-20100323993-A1 USES OF PENTAMIDINE AND RELATED COMPOUNDS MBNL1, MTPN, RRBP1 TMPRSS2 3609/4885FURIN 3879/4885AOC1 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.